FTC Expands Patent Listing Challenges, Targeting More Than 300 Junk …
WEBApr 30, 2024 · Today, the Federal Trade Commission expanded its campaign against pharmaceutical manufacturers’ improper or inaccurate listing of patents in the Food and Drug Administration’s (FDA) Orange Book, disputing junk patent listings for diabetes, weight loss, asthma, and COPD drugs, including …
FTC Warns ‘Junk Patents’ Could Make Drugs Like Ozempic …
WEBApr 30, 2024 · The FTC sent warning letters to 10 pharmaceutical companies—including Novo Nordisk, AstraZeneca, GlaxoSmithKline and Teva—disputing more than 300 “junk” patent listings across 20 different...
FTC targets ‘junk patents’ on Ozempic, other top drugs - Yahoo …
WEBMay 1, 2024 · The move broadens the antitrust regulator’s campaign against allegedly “improper or inaccurate” patent listings by drugmakers to include top-selling medicines for weight loss, diabetes, asthma...
FTC Targets ‘Junk’ Patent Listings on Ozempic and Other Drugs
WEBApr 30, 2024 · FTC Targets ‘Junk’ Patent Listings on Ozempic and Other Drugs. The antitrust cop says patent listings stall generic competition, keeping prices high for diabetes drugs, inhalers and...
Novo’s Blockbuster Ozempic Among FTC’s Latest Patent Targets
WEBApr 30, 2024 · Christopher Yasiejko. Blockbusters including Novo Nordisk’s Ozempic and Victoza are among 20 branded drugs the Federal Trade Commission is targeting as it challenges more than 300 “junk patent listings” in the FDA’s registry of approved drugs in an effort to accelerate generic competition.
The FTC’s Criticism of “Junk” Orange Book Filings: The Latest …
WEBMay 27, 2024 · In September 2023, the Federal Trade Commission (FTC) embarked upon a campaign against pharmaceutical manufacturers’ “improper listing” of patents in the Food and Drug Administration’s (FDA) Orange Book by issuing a policy statement putting market participants on notice that it intends to scrutinize improper …
FTC targets Novo's Ozempic among 300-plus 'junk' patents
WEBMay 1, 2024 · The FTC argues those patents for altogether 20 brand-name products are “junk” listings that could be used by pharma companies to stymie competition and inflate drug prices. AstraZeneca,...
FTC Targets ‘Junk’ Patent Listings on Ozempic and Other Drugs
WEBThe FTC issued letters to 10 companies Tuesday morning, warning them their patent listings were invalid. It also notified the FDA that it disputes the patent listings.
US challenges 'bogus' patents on Ozempic and other drugs in …
WEBUpdated 2:36 PM PDT, April 30, 2024. WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand-name drugs, including the blockbuster weight-loss injection Ozempic, in the latest effort by the Biden administration targeting pharmaceutical industry practices that drive up prices.
Ozempic and 19 other drugs have 'junk' patents, FTC says - Quartz
WEBApr 30, 2024 · The U.S. Federal Trade Commission (FTC) announced on Tuesday that it is disputing over 300 patent listings across 20 different brand name drugs in an effort to promote competition and lower...
Skip to content